1. Pink Sheet
  2. >>Market Access
  3. >>Health Technology Assessment

Discounts Help Prompt UK’s NICE Turnaround on Dupixent and Ocrevus

 
• By Francesca Bruce

After initially saying no, the UK health technology appraisal body, NICE, has recommended for use on the National Health Service Sanofi/Regeneron’s Dupixent and Roche’s Ocrevus. Confidential discounts helped convince NICE.

nerve cells, concept for neurodegenerative and neurological disease
Nerve signals between the brain and other parts of the body are disrupted by damage to the myelin and nerve fibers in patients with multiple sclerosis.

NICE, the health technology appraisal institute for England and Wales, has issued two pieces of final draft guidance reversing earlier recommendations that found Roche’s multiple sclerosis drug Ocrevus (ocrelizumab) and Sanofi/Regeneron Pharmaceuticals Inc.’s Dupixent (dupilumab) for eczema to be too expensive for use on the National Health Service. In both cases discounts helped secure a turnaround.

Final draft guidance published by NICE on June 22 recommends Ocrevus for treating relapsing remitting MS (RRMS) in adults with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek

 
• By Neena Brizmohun

Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.

Industry Criticizes Dutch Decision To Slash PARP Inhibitor Reimbursement

 
• By Francesca Bruce

ZIN, the Dutch health technology assessment body, estimates that the number of patients eligible for treatment with a PARP inhibitor will be halved following a reassessment of drugs in the class.

Canada Unveils Draft List of Essential Drugs For Universal Pharmacare

 
• By Neena Brizmohun

The list of essential prescription drugs and related products will shape Canada’s first national formulary for the country’s universal pharmacare program.

Engage With HTA Body NICE Before Submitting MAA, UK Govt Tells Companies

 
• By Neena Brizmohun

The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.

More from Market Access